-
Press Release
2019/01/28
Abnova & Nippon Kayaku Signed Exclusive ACTN4 Supply and Commercialization Agreement for Lung Cancer IVD Market in Japan
-
Press Release
2018/10/09
Abnova & BioView Successfully Developed All-in-One Imaging System and Artificial Intelligence (AI) Solution for Identification of Circulating Tumor and Fetal Cells (CTCs and CFCs
-
Press Release
2018/09/10
Abnova T-cell Therapy Demonstrated Efficacy against Large Solid Tumors in Preclinical Studies
-
Press Release
2018/07/31
Abnova Launches Cell-Based, Non-Invasive Liquid Biopsy of Circulating Endothelial Progenitor Cells (EPC) Targeting Healthy and Anti-Aging Markets
-
Press Release
2018/06/26
Abnova & Yourgene Collaborate to Accelerate Next Generation Sequencing Capability and Analysis of Circulating Tumor Cell and Circulating Fetal Cell in Taiwan
-
Press Release
2018/05/21
Abnova Expands its SELECT™ Non-Invasive Fetal Cell Liquid Biopsy Platform with Clinical Validation Study in Japan Sanno Hospital
-
Press Release
2018/03/08
Abnova Races Ahead to Develop and Commercialize Autologous T Cell Therapy for Solid Tumors
-
Press Release
2018/02/08
Abnova Gained Japan PMDA Permission to Advances ACTN4 In Vitro Diagnostic (IVD) Biomarker for Lung Adenocarcinoma into Clinical Trial in Japan
-
Press Release
2018/01/11
Abnova developed and submitted RoHS compatible CytoQuest™ CR System for SGS and CE-IVD certification
-
Press Release
2017/09/11
Abnova Enters Third-Party Diagnostic Market in China